Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chul Ahn
Daniel Ahn

Showing results (581-590 of 593) with videos related to

Pageof 60
Sort By:
Nature Genetics|November 13, 2007
Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissectionsDong-Chuan Guo, Hariyadarshi Pannu, Van Tran-Fadulu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Translational Gastroenterology and Hepatology|June 15, 2026
Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trialsPedro Luiz Serrano Uson Junior, Fernando Moura, Frederico Monfardini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 1, 2018
Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancerMitchell L Ramsey, Erin Talbert, Daniel Ahn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective StudyPedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
JAMA Network Open|September 12, 2025
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary TumorsHimil Mahadevia, Umair Majeed, Jaydeepbhai Patel, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 60

Showing results (581-590 of 593) with videos related to

Sort By:
Pageof 60
Nature Genetics|November 13, 2007
Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissectionsDong-Chuan Guo, Hariyadarshi Pannu, Van Tran-Fadulu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Translational Gastroenterology and Hepatology|June 15, 2026
Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trialsPedro Luiz Serrano Uson Junior, Fernando Moura, Frederico Monfardini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 1, 2018
Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancerMitchell L Ramsey, Erin Talbert, Daniel Ahn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective StudyPedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
JAMA Network Open|September 12, 2025
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary TumorsHimil Mahadevia, Umair Majeed, Jaydeepbhai Patel, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 60